Author: Benzinga Newsdesk | March 25, 2025 07:05am
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.24) per share from the same period last year.